DISCOVER OUR NEWS
TheraPPI Announces Publication of Preclinical Data in Nature Communications, Demonstrating the Inhibition of ERK/MyD88 Interaction as a Promising Cancer Treatment
TheraPPI scientists publish preclinical data in Nature Communications, demonstrating the inhibition of ERK/MyD88 interaction as a promising cancer treatment
TheraPPI Bioscience Awarded the French Tech Emergence Grant
TheraPPI has been awarded the French Tech Emergence Grant by BPI France in the context of the “Programme France 2030”.
TheraPPI Bioscience Awarded Reputable French Tech Seed Label
The Pouss@LYS consortium has recently given a favorable recommendation on French Tech Seed label to TheraPPI
TheraPPI Bioscience awarded a Fongit Innovation Fund (FIF) seed loan
The Fondation Genevoise pour l’Innovation Technologique has granted a FIF seed loan of CHF100 000 to TheraPPI
TheraPPI Bioscience announces an exclusive license agreement with PULSALYS to develop novel drugs in oncology and rare diseases
PULSALYS and TheraPPI Bioscience SAS enter into an exclusive and global license agreement to develop drugs targeting a novel Ras-MAPK pathway protein interaction